12/3
09:42 am
dsnky
Is Daiichi Sankyo Now an Opportunity After a 26% Share Price Slide? [Yahoo! Finance]
Low
Report
Is Daiichi Sankyo Now an Opportunity After a 26% Share Price Slide? [Yahoo! Finance]
12/3
07:00 am
dsnky
Federal Circuit Court of Appeals Vacates Infringement Judgment and Damages Award in Dispute between Daiichi Sankyo and Seagen
Medium
Report
Federal Circuit Court of Appeals Vacates Infringement Judgment and Damages Award in Dispute between Daiichi Sankyo and Seagen
11/25
03:28 am
dsnky
Allegro and American Regent sign exclusive licensing deal for SynoglideTM, a novel osteoarthritis treatment in animal health, valued at up to $35 million [Yahoo! Finance]
Low
Report
Allegro and American Regent sign exclusive licensing deal for SynoglideTM, a novel osteoarthritis treatment in animal health, valued at up to $35 million [Yahoo! Finance]
11/25
02:30 am
dsnky
Allegro and American Regent sign exclusive licensing deal for SynoglideTM, a novel osteoarthritis treatment in animal health, valued at up to $35 million
Medium
Report
Allegro and American Regent sign exclusive licensing deal for SynoglideTM, a novel osteoarthritis treatment in animal health, valued at up to $35 million
11/21
05:30 am
dsnky
Daiichi Sankyo (OTCMKTS:DSNKY) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
Medium
Report
Daiichi Sankyo (OTCMKTS:DSNKY) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
11/12
10:36 am
dsnky
General Proximity Announces Multi-Target Collaboration with Daiichi Sankyo to Discover and Advance Novel Oncology Therapeutics Using OmniTAC™ Platform [Yahoo! Finance]
Low
Report
General Proximity Announces Multi-Target Collaboration with Daiichi Sankyo to Discover and Advance Novel Oncology Therapeutics Using OmniTAC™ Platform [Yahoo! Finance]
11/12
10:00 am
dsnky
General Proximity Announces Multi-Target Collaboration with Daiichi Sankyo to Discover and Advance Novel Oncology Therapeutics Using OmniTAC™ Platform
Low
Report
General Proximity Announces Multi-Target Collaboration with Daiichi Sankyo to Discover and Advance Novel Oncology Therapeutics Using OmniTAC™ Platform
11/10
07:28 am
dsnky
DS3610 Enters Clinical Development in Patients with Advanced Solid Tumors as First STING Agonist ADC in Industry-Leading ADC Portfolio of Daiichi Sankyo [Yahoo! Finance]
High
Report
DS3610 Enters Clinical Development in Patients with Advanced Solid Tumors as First STING Agonist ADC in Industry-Leading ADC Portfolio of Daiichi Sankyo [Yahoo! Finance]
11/10
07:00 am
dsnky
DS3610 Enters Clinical Development in Patients with Advanced Solid Tumors as First STING Agonist ADC in Industry-Leading ADC Portfolio of Daiichi Sankyo
High
Report
DS3610 Enters Clinical Development in Patients with Advanced Solid Tumors as First STING Agonist ADC in Industry-Leading ADC Portfolio of Daiichi Sankyo
11/9
06:02 pm
dsnky
3 Asian Stocks Estimated To Be Trading At Discounts Of Up To 37.6% [Yahoo! Finance]
High
Report
3 Asian Stocks Estimated To Be Trading At Discounts Of Up To 37.6% [Yahoo! Finance]
11/6
01:57 am
dsnky
Daiichi Sankyo Company, Limited (DSNKY) Q2 FY2025 Earnings Call Transcript [Seeking Alpha]
Medium
Report
Daiichi Sankyo Company, Limited (DSNKY) Q2 FY2025 Earnings Call Transcript [Seeking Alpha]
10/30
09:18 pm
dsnky
DESTINY-Lung06 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Overexpressing Metastatic Non-Squamous Non-Small Cell Lung Cancer [Yahoo! Finance]
Low
Report
DESTINY-Lung06 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Overexpressing Metastatic Non-Squamous Non-Small Cell Lung Cancer [Yahoo! Finance]
10/30
09:00 pm
dsnky
DESTINY-Lung06 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Overexpressing Metastatic Non-Squamous Non-Small Cell Lung Cancer
Medium
Report
DESTINY-Lung06 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Overexpressing Metastatic Non-Squamous Non-Small Cell Lung Cancer
10/21
05:12 pm
dsnky
Daiichi Sankyo Company, Limited (DSNKY) Discusses ESMO 2025 Highlights With Focus on Key Breast Cancer Trial Data and Regulatory Submissions Transcript [Seeking Alpha]
Low
Report
Daiichi Sankyo Company, Limited (DSNKY) Discusses ESMO 2025 Highlights With Focus on Key Breast Cancer Trial Data and Regulatory Submissions Transcript [Seeking Alpha]
10/19
10:23 pm
dsnky
What Recent Oncology Deal Means for Daiichi Sankyo Shares in 2025 [Yahoo! Finance]
Low
Report
What Recent Oncology Deal Means for Daiichi Sankyo Shares in 2025 [Yahoo! Finance]
10/19
09:17 am
dsnky
DS-3939 Shows Promising Preliminary Clinical Activity in Patients with Advanced Solid Tumors in Phase 1/2 Trial [Yahoo! Finance]
Low
Report
DS-3939 Shows Promising Preliminary Clinical Activity in Patients with Advanced Solid Tumors in Phase 1/2 Trial [Yahoo! Finance]
10/19
09:00 am
dsnky
DS-3939 Shows Promising Preliminary Clinical Activity in Patients with Advanced Solid Tumors in Phase 1/2 Trial
Low
Report
DS-3939 Shows Promising Preliminary Clinical Activity in Patients with Advanced Solid Tumors in Phase 1/2 Trial
10/19
02:30 am
dsnky
DATROWAY® Demonstrated an Unprecedented Median Overall Survival Improvement of Five Months Vs Chemotherapy as First-line Treatment for Patients with Metastatic Triple Negative Breast Cancer for Whom Immunotherapy Was Not an Option in TROPION-Breast02
Low
Report
DATROWAY® Demonstrated an Unprecedented Median Overall Survival Improvement of Five Months Vs Chemotherapy as First-line Treatment for Patients with Metastatic Triple Negative Breast Cancer for Whom Immunotherapy Was Not an Option in TROPION-Breast02
10/18
10:49 am
dsnky
ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery resulted in a pathologic complete response in 67% of patients with high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11 Phase III trial [Yahoo! Finance]
Low
Report
ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery resulted in a pathologic complete response in 67% of patients with high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11 Phase III trial [Yahoo! Finance]
10/18
10:30 am
dsnky
ENHERTU® Reduced the Risk of Disease Recurrence or Death by 53% Versus T-DM1 in Patients with High-Risk HER2 Positive Early Breast Cancer Following Neoadjuvant Therapy in DESTINY-Breast05 Phase 3 Trial
Low
Report
ENHERTU® Reduced the Risk of Disease Recurrence or Death by 53% Versus T-DM1 in Patients with High-Risk HER2 Positive Early Breast Cancer Following Neoadjuvant Therapy in DESTINY-Breast05 Phase 3 Trial
10/18
10:30 am
dsnky
ENHERTU® Followed by THP Before Surgery Resulted in a Pathologic Complete Response in 67% of Patients with High-Risk HER2 Positive Early-Stage Breast Cancer in DESTINY-Breast11 Phase 3 Trial
Low
Report
ENHERTU® Followed by THP Before Surgery Resulted in a Pathologic Complete Response in 67% of Patients with High-Risk HER2 Positive Early-Stage Breast Cancer in DESTINY-Breast11 Phase 3 Trial
10/17
10:00 am
dsnky
DATROWAY® Plus Rilvegostomig Showed Promising Tumor Responses in Patients with Metastatic Urothelial Cancer in TROPION-PanTumor03 Phase 2 Trial
Low
Report
DATROWAY® Plus Rilvegostomig Showed Promising Tumor Responses in Patients with Metastatic Urothelial Cancer in TROPION-PanTumor03 Phase 2 Trial
10/13
07:11 am
dsnky
Daiichi Sankyo Continues to Transform Standards of Care for Patients with Three Landmark Breast Cancer Trials and Additional Data Across Industry-Leading ADC Portfolio at ESMO [Yahoo! Finance]
Low
Report
Daiichi Sankyo Continues to Transform Standards of Care for Patients with Three Landmark Breast Cancer Trials and Additional Data Across Industry-Leading ADC Portfolio at ESMO [Yahoo! Finance]
10/13
07:00 am
dsnky
Daiichi Sankyo Continues to Transform Standards of Care for Patients with Three Landmark Breast Cancer Trials and Additional Data Across Industry-Leading ADC Portfolio at ESMO
Low
Report
Daiichi Sankyo Continues to Transform Standards of Care for Patients with Three Landmark Breast Cancer Trials and Additional Data Across Industry-Leading ADC Portfolio at ESMO
10/6
07:30 am
dsnky
DATROWAY® (datopotamab deruxtecan-dlnk) improved OS and PFS in TROPION-Breast02 [Yahoo! Finance]
Medium
Report
DATROWAY® (datopotamab deruxtecan-dlnk) improved OS and PFS in TROPION-Breast02 [Yahoo! Finance]